Arca
Skip to content
Tools
Tools

Duchenne muscular dystrophy

Drug research and approvals for duchenne muscular dystrophy: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 21, 2026, 62 studies of duchenne muscular dystrophy are recruiting on ClinicalTrials.gov, Health Canada has authorized 52 drug trials for it since 2013, FDA has 10 approved and 84 open orphan designations naming it, and the EU has 2 authorised medicines for it.

  • Recruiting worldwide: 62
  • Trials authorized in Canada: 52
  • FDA orphan approvals: 10
  • EU medicines: 2

Recruiting now

Newest posted first, of 62 recruiting on ClinicalTrials.gov ↗

Drug pipeline

Each drug at the furthest stage it has reached for this condition, from ChEMBL's drug indications

Approved 9

Phase 3 12 of 14

Phase 2 12 of 17

Phase 1 or earlier 11

How its trials ended

410 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrong

Of the 101 whose ending is known, 40% met their primary endpoint, 6% missed it and 54% stopped early.

  • Completed, result not reported16039%
  • Ongoing11328%
  • Met its primary endpoint4010%
  • Status unknown369%
  • Stopped: other or unclear246%
  • Stopped: lack of efficacy123%
  • Stopped: sponsor or business decision113%
  • Missed its primary endpoint61%
  • Stopped: enrollment or feasibility51%
  • Stopped: safety2<1%
  • Stopped: funding1<1%

Trials authorized in Canada

The 10 newest of 52; search them all in Canada trials
Aug 18, 2026A 2-part, randomized, double-blind, placebo-controlled study in participants with Duchenne muscular dystrophy amenable to exon 44 skipping with an initial…ENTR-601-44Entrada TherapeuticsPending
Jul 29, 2026A phase 2 open-label extension study to assess the safety and efficacy of brogidirsen in boys with Duchenne muscular dystrophy (DMD)Brogidirsen (NS-089/NCNP-02)NS Pharma IncPending
Feb 20, 2026A phase 3, randomized, double-blind, placebo-controlled, global study with an open-label extension to evaluate the efficacy and safety of intravenous aoc 1044…Aoc 1044Avidity BiosciencesOngoing
Dec 12, 2025A phase 2a, randomized, double-blind, placebo-controlled dose comparison and exploratory efficacy study of orally administered SAT-3247 in ambulatory dmd…SAT-3247Satellos BioscienceOngoing
Aug 15, 2025A phase 3, multicenter, randomized, double-blind, placebo-controlled study to investigate the efficacy of a single intravenous dose of SGT-003 in ambulant…SGT-003Solid BiosciencesOngoing
Aug 6, 2025A phase 1/2, open-label, dose escalation study to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple intravenous doses of bmn…Bmn 351BioMarin PharmaceuticalOngoing
Jan 22, 2025A phase 1/2, first in human, multiple-dose, 2-part study to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of NS-050/NCNP-03 in boys…NS050/NCNP-03NS Pharma IncOngoing
Jan 20, 2025A phase 2 study to assess the efficacy, safety, tolerability, and pharmacokinetics of NS-089/NCNP-02 in boys with Duchenne muscular dystrophy (DMD)Brogidirsen (NS-089/NCNP-02)NS Pharma IncOngoing
Nov 1, 2024A phase 1/2/3 open-label, study to evaluate the safety, tolerability, efficacy, pharmacodynamics, and pharmacokinetics of intravenous RGX-202 gene therapy in…RGX-202REGENXBIOOngoing
Aug 30, 2024A phase 3, multinational, randomized, double-blind, placebocontrolled systemic gene transfer therapy study to evaluate the safety and efficacy of SRP-9001 in…Delandistrogene moxeparvovec (SRP-9001)Sarepta TherapeuticsPending

FDA orphan designations

Approved first, then open designations, newest first; 15 of 94
Jun 20, 2024ElevidysTreatment of Duchenne muscular dystrophy (DMD) in individuals at least 4 years of age for patients who are ambulatory and have a confirmed…Sarepta Therapeutics, Inc.Approved
Mar 21, 2024DuvyzatTreatment of Duchenne muscular dystrophy (DMD) in patients 6 years of age and olderItalfarmaco SpAApproved
Oct 26, 2023AgamreeTreatment of Duchenne muscular dystrophy (DMD) in patients 2 years of age and olderCatalyst Pharmaceuticals, Inc.Approved
Jun 22, 2023ElevidysTreatment of ambulatory pediatric patients aged 4 through 5 years with Duchenne muscular dystrophy (DMD) with a confirmed mutation in the…Sarepta Therapeutics, Inc.Approved
Feb 25, 2021Amondys 45Treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 45…Sarepta Therapeutics, Inc.Approved
Aug 12, 2020ViltepsoVILTEPSO is indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that…NS Pharma, Inc.Approved
Dec 12, 2019Vyondys 53VYONDYS 53 is indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene…Sarepta Therapeutics, Inc.Approved
Jun 7, 2019EmflazaEMFLAZA is indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients 2 years of age and older.PTC Therapeutics, Inc.Approved
Feb 9, 2017EmflazaTreatment of Duchenne Muscular Dystrophy in patients 5 years of age and olderPTC Therapeutics, Inc.Approved
Sep 19, 2016Exondys 51Treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 51…Sarepta Therapeutics, Inc.Approved
Oct 24, 2026RNA editing antisense oligonucleotide against exon 45 of…Treatment of Duchenne muscular dystrophyEntrada Therapeutics, Inc.Designated
Sep 22, 2026Human umbilical cord derived mesenchymal stem cellsTreatment of Duchenne muscular dystrophySignature BiologicsDesignated
Jun 11, 2026TegacoratTreatment of Duchenne muscular dystrophyGRT Therapeutics, Inc.Designated
Apr 28, 20264-chloro-N-{4-[(morpholin-4-yl) methyl] phenyl}benzamide…Treatment of Duchenne muscular dystrophyGEn1E Lifesciences Inc.Designated
Apr 17, 2026Small-molecule histone deacetylase 6 inhibitorTreatment of Duchenne muscular dystrophyTenaya Therapeutics, Inc.Designated

Medicines authorised in the EU

Newest first
Jun 6, 2025DuvyzatGivinostat · orphanItalfarmaco S.p.A.EMA ↗
Dec 14, 2023AgamreeVamorolone · orphanSanthera Pharmaceuticals (Deutschland) GmbHEMA ↗

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.